phone image +91 22 68948500, 68948500

Divis Laboratories Ltd

BSE Code : 532488 | NSE Symbol : DIVISLAB | ISIN:INE361B01024| SECTOR: - |


BSE

4,880.70

-49.50 (-1.00%)

30-Nov-2021 EOD

/ Volume 280564
Prev. Close

4,930.20

Open Price

4,905.00

Bid Price (QTY)

0.00(0)

Offer Price (QTY)

0.00(0)

Today’s High/Low 4,950.00 - 4,950.00

52 wk High/Low 5,425.00 - 3,154.50

NSE

4,878.80

-42.55 (-0.86%)

30-Nov-2021 EOD

/ Volume 280564
Prev. Close

4,921.35

Open Price

4,930.00

Bid Price (QTY)

0.00(0)

Offer Price (QTY)

4,878.80(979)

Today’s High/Low 4,949.70 - 4,949.70

52 wk High/Low 5,425.10 - 3,153.30

Key Stats

MARKET CAP (RS CR) 130881.32
P/E 62.1
BOOK VALUE (RS) 372.8905965
DIV (%) 1000
MARKET LOT 1
EPS (TTM) 79.39
PRICE/BOOK 13.2215723493043
DIV YIELD.(%) 0.41
FACE VALUE (RS) 2
DELIVERABLES (%) 43.63

News & Announcements

08-Nov-2021

Divis Laboratories Ltd Slips 7.72%, S&P BSE Healthcare index Shed 1.43%

08-Nov-2021

IndusInd Bank Ltd leads losers in 'A' group

08-Nov-2021

Divis Laboratories Ltd - Divis Laboratories Limited - Outcome of Board Meeting

06-Nov-2021

Divi's Laboratories consolidated net profit rises 16.72% in the September 2021 quarter

29-Oct-2021

Divis Laboratories announces board meeting date

31-Jul-2021

Divis Laboratories to convene board meeting

20-Jul-2021

Divis Laboratories to conduct AGM

29-May-2021

Board of Divis Laboratories recommends final dividend

Corporate Actions

Bonus
Splits
Dividends
Rights
Capital Structure
Book Closure
Board Meeting
AGM
EGM

Peers Comparsion

Select Company Name BSE Code NSE Symbol
Aarey Drugs & Pharmaceuticals Ltd 524412 AAREYDRUGS
Aarti Drugs Ltd 524348 AARTIDRUGS
Add Life Pharma Ltd 524665
Adithya Alkaloids Pvt Ltd 524320
Alpha Drug India Ltd(merged) 500006 ALPHADRUG
Ami Organics Ltd 543349 AMIORG
Anuh Pharma Ltd 506260
Anus Laboratories Ltd 532981
Arch Pharmalabs Ltd 524729
Aster Drugs & Pharmaceuticals Ltd 40286
Auro Laboratories Ltd 530233
Auromed Ltd 532103
Bacil Pharma Ltd 524516
Beta Drugs Ltd 535022 BETA
Betalact Laboratories Ltd 531238
Biotech Synergy Ltd 40183
Cheminor Drugs Ltd (Merged) 524140 CHEMNODRUG
Chemo Pharma Laboratories Ltd 506365
Chemox Chemical Industries Ltd (Wound-up) 512042 CHEMOXCHEM
Chiplun Fine Chemicals Ltd 530417
Core Laboratories Ltd (Merged) 506963
Coromandel Pharmaceuticals Ltd 524524
Daurala Organics Ltd(merged) 524256 DAURALAORG
Denis Chem Lab Ltd 537536
Dishman Pharmaceuticals and Chemicals Ltd(Merged) 532526 DISHMAN
Dynachem Pharmaceuticals (Export) Ltd 524562 DYNAPHARMA
Elder Pharmaceuticals Ltd 532322 ELDERPHARM
Elegant Pharmaceuticals Ltd 524344
Emergy Phaarma Ltd 524812
Everest Organics Ltd 524790
Fermenta Biotech Ltd 506414
Fernhill Industries Ltd 531466
Fine Drugs And Chemicals Ltd (Merged) 524782
Gennex Laboratories Ltd 531739
Gland Pharma Ltd 543245 GLAND
Godavari Drugs Ltd 530317
Granules India Ltd 532482 GRANULES
Gujarat Lyka Organics Ltd (Merged) 506930
Gujarat Themis Biosyn Ltd 506879 GUJTHEMIS
Hallmark Drugs & Chemicals Ltd 531407
Harshita Ltd 531347
Hikal Ltd 524735 HIKAL
Hiran Orgochem Ltd 506170
Hi-Tech Drugs Ltd 524424
Ishita Drugs & Industries Ltd 524400
J K Pharmachem Ltd 500218 JKPHARMA
Janak Intermediates Ltd 524380
Jubilant Pharmova Ltd 530019 JUBLPHARMA
Kaprinas Pharmaceuticals & Chemicals Ltd 530147
Kimia Biosciences Ltd 530313
Konar Organics Ltd 526933
Krebs Biochemicals & Industries Ltd 524518 KREBSBIO
Kwality Pharmaceuticals Ltd 539997
Lactose (India) Ltd 524202
Larite Industries Ltd 512325
Lupin Ltd 500257 LUPIN
Magnum Intermediates Ltd 40177
Manav Pharma Ltd 524390
Marksans Pharma Ltd 524404 MARKSANS
Medicorp Technologies India Ltd (Merged) 532108 MEDICOTECH
Nagarjuna Drugs Ltd 530064
Nagarjuna Nature Base Ltd 40353
Nalin Chemicals Ltd 531292
Natco Laboratories Ltd (Merged) 500299 NATCOLABS
Nectar Lifescience Ltd 532649 NECLIFE
Neuland Laboratories Ltd 524558 NEULANDLAB
NGL Fine Chem Ltd 524774
Nutraplus India Ltd 524764
Orchid Pharma Ltd 524372 ORCHPHARMA
Paam Drugs & Pharmaceuticals Ltd 524462 PAAMDRUG
Pan India Drugs & Chemicals Ltd 524560
Panchsheel Organics Ltd 531726 PANCHSHEEL
Par Drugs & Chemicals Ltd 535341 PAR
Parabolic Drugs Ltd 533211 PARABDRUGS
Parmax Pharma Ltd 540359
Pharmed Chemicals Ltd 524733
Piramal Phytocare Ltd(Merged) 532979 PIRPHYTO
Plama Laboratories Ltd (Merged) 524798
Pradeep Drug Company Ltd (Merged) 524246
Ratna Drugs Ltd 524382
Regent Chemicals Ltd 506989
Richline Pharma Ltd 524460
Roopa Industries Ltd 530991
Rupal Chemical Industries Ltd (Merged) 524705
Rupangi Impex Ltd (Wound-up) 512606 RUPANGIMPX
S S Organics Ltd 524636
Samrat Pharmachem Ltd 530125
Sequent Scientific Ltd 512529 SEQUENT
Sharvani Pharmaceuticals Ltd 40159
Shasun Pharmaceuticals Ltd(Merged) 524552 SHASUNPHAR
Shilpa Medicare Ltd 530549 SHILPAMED
Shilpax Laboratories Ltd 524482
Shrishma Fine Chemicals (Karnataka) Ltd 507000
Siris Ltd 524746 SIRIS
Smruthi Organics Ltd 540686
SMS Pharmaceuticals Ltd 532815 SMSPHARMA
Southern Herbals Ltd 500395 SOUTHNHERB
Sri Chakra Remedies Ltd (Merged) 507484
Stellar Drugs Ltd 524612
Sterling Basic Organics Ltd 524644
Suven Life Sciences Ltd 530239 SUVEN
Swet-Chem Antibiotics Ltd 531186
Targof Pure Drugs Ltd 40230
Teem Laboratories Ltd 507761
Transchem Ltd 500422 TRANSCHEM
Umedix India Ltd 524822
Venkat Pharma Ltd 532093
Venmax Drugs & Pharmaceuticals Ltd 531015
Vera Laboratories Ltd (Merged) 40228
Vitara Chemicals Ltd 524646 VITARACHEM
Vivo Bio Tech Ltd 511509
Vorin Laboratories Ltd (Merged) 524508
Wanbury Ltd 524212 WANBURY
Zora Pharma Ltd(merged) 524438
Zyden Gentec Ltd 530091

Share Holding

Category No. of shares Percentage
Total Foreign 55962409 21.08
Total Institutions 43418056 16.36
Total Govt Holding 0 0.00
Total Non Promoter Corporate Holding 3686841 1.39
Total Promoters 137899200 51.95
Total Public & others 24503666 9.23
Total 265468580 100
  • Total Foreign
  • Total Institutions
  • Total Govt Holding
  • Total Non Promoter Corporate Holding
  • Total Promoters
  • Total Public & others

About Divi's Laboratories Ltd

Divi's Laboratories Ltd is an India based manufacturer of Active Pharmaceutical Ingredients (APIs) and Intermediates. The company is engaged in manufacture of leading generic compounds, Nutraceutical ingredients and custom synthesis of APIs and intermediates for global innovator companies. Divis is among the largest pharmaceutical companies in India with a portfolio of 120 products across diverse therapeutic areas. The company has four manufacturing facilities and market presence across several countries. The first facility is located at village Lingojigudem in Yadadri Bhuvanagiri District near Hyderabad (Telangana) comprises 11 multipurpose production blocks with finished product areas for APIs. The second manufacturing unit is an export oriented unit located at village Chippada, Bheemunipatnam Mandal, about 30 KM from the port city of Visakhapatnam (Andhra Pradesh) on the east coast situated on a 100-acre site. The third facility is located at village Chippda situated on a sprawling 267-acre site and is a Special Economic Zone (SEZ) Unit in Pharma Sector. The fourth facility is located at the company's Pharma SEZ at village Chippada. The company has two subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products and to provide a greater reach to customers within these regions. The company has Research Centers at Sanathnagar, Hyderabad and at the manufacturing sites. Research Centre at Sanathnagar primarily focuses on custom synthesis, contract research for MNC companies as also future generics involving processes like route design, route selection, establishing gram scale process and structural confirmation. Divi's Laboratories Ltd was established in the year 1990 as Divis Research Center (DRC) with Research & Development as their prime fundamental. During the year 1991-93, the company successfully developed several commercial processes for intermediates and bulk actives and supplies to manufacturing majors. In the year 1994, they changed their name to Divis Laboratories Ltd to reflect their growing area of operations. In the year 1995, the company started operations in their manufacturing facility (Unit I) at Choutuppal near Hyderabad. In the year 1997, the company was certified as ISO-9002 compliant by SGS-Yarsley of U.K. In the year 1999, European Directorate gave a 'Certificate of Suitability' (CoS) for Naproxen produced by the company. In the year 2001, the company received OHSAS-18001 Certification from BVQI of London for their Occupational Health and Safety Management Systems. In the year 2002, the company commenced setting up of their second manufacturing facility (Unit II) at Chippada near Visakhapatnam. In the year 2003, they opened a new research center christened 'DRC-Vizag' for fundamental research in selected niche business core segments. The company went for initial public offering (IPO) and their shares were listed on Bombay Stock Exchange and National Stock Exchange. In the year 2004, the company invested an amount of Rs 3035.21 lakh towards capital expenditure at their manufacturing facilities at Choutuppal (Unit-I) and Chippada (Unit-II) for additional machinery installed at both Unit-I and Unit-II. In the year 2006, the company received letter of approval from Ministry of Commerce, Government of India, for setting up a sector-specific special economic zone (SEZ) for pharmaceutical ingredients at Chippada, Bheemunipatnam in Visakhapatnam with investment of Rs 200 crore. The company's second manufacturing site at Chippada, was converted into Export Oriented Unit (EOU) and started operations as EOU from June 1, 2006. During the year 2006-07, the company developed an SEZ titled 'Divi's Pharma SEZ' on a 250-acre site at Chippada, Visakhapatnam. During the year 2007-08, the company set up new production as well as utility facilities in SEZ and EOU Units, and enhanced existing capacities at Unit-1. They commissioned Nutraceuticals Manufacturing facility at Divi's Pharma SEZ and commenced commercial operations effective June 1, 2008. During the year 2008-09, the company added 9 products to their product portfolio of which 4 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates. During the year 2009-10, they added 7 products to their product portfolio of which 2 are generic APIs and intermediates and 5 are custom synthesis APIs and intermediates. During the year 2010-11, the company added 21 products to their product portfolio of which 8 are generic APIs and intermediates and 13 are custom synthesis APIs and intermediates. The company set up a new facility called 'DSN SEZ Unit' at Chippada in Visakhapatnam at an estimated cost of Rs 200 crore for creating additional capacities for the new opportunities in generic as well as custom synthesis segment. The DSN SEZ Unit commenced commercial operations from June 1, 2011. During the year 2012-13, the company added 9 products to its product portfolio of which 3 are generic APIs and intermediates and 6 are custom synthesis APIs and intermediates. In 2014, the Korean Food and Drug Administration (KFDA) carried out inspection of the company's Visakhapatnam Unit-2 for the third time. During the year, fourth US FDA inspection was carried out at the company's Visakhapatnam Unit-2. Also during the year, fifth US FDA inspection was carried out for Unit-1. During the year, COFEPRIS (Mexico) inspected the company's Visakhapatnam Unit-2 for the first time. COFEPRIS (Mexico) also inspected the company's Choutuppal Unit-1 in Telangana for the first time in the year 2014. On 19 February 2016, Divi's Laboratories announced that it has had a successful inspection by the US-FDA for its Unit-2 at Chippada, Bheemunipatnam near Visakhapatnam during February 2016 with no observations. The Board of Directors of Divi's Laboratories at its meeting held on 12 August 2016 approved and ratified one-time ex-gratia of an aggregate amount of Rs 79 crore to the employees and whole-time directors of the company on the occasion of completion of 25 years of formation of the company. On 8 April 2017, Divi's Laboratories announced that the US-FDA has exempted some more products manufactured at the company's Unit-II at Visakhapatnam from import alert issued under clauses 66-40 and 99-32 of the FDA regulations. On 22 April 2017, Divi's Laboratories announced that the US-FDA has issued a warning letter for the company's Unit-II at Visakhapatnam. On 4 August 2017, Divi's Laboratories announced that the inspection of the Unit-2 Visakhapatnam was completed successfully by HPRA (Ireland) and JAZMP (Slovenia). The inspection was focused on follow up on the effectiveness of the CAPA implemented from the last JAZMP inspection and general GMP inspection of the site. On 15 November 2017, Divi's Laboratories announced that the US-FDA has lifted/removed import alert 66-40 imposed on the company's Unit-II at Visakhapatnam. On 18 November 2017, Divi's Laboratories announced that the company has received an Establishment Inspection Report (EIR) from US-FDA for Unit-II at Visakhapatnam, as closure of audit by FDA. Earlier, the company had informed the stock exchanged that its Unit-II at Visakhapatnam was inspected by US-FDA in September 2017 wherein a Form-483 was issued with 6 observations. On 16 May 2018, Divi's Laboratories announced that its Unit-I at Choutuppal, Telangana has had an inspection by the US-FDA from 14th May 2018 to 16th May, 2018. This was a general cGMP inspection by the FDA. The inspection has been concluded with no 483 observations. As on 31 March 2018, the company has two overseas subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products. During the year 2017-18, the company is making capacity additions at the existing manufacturing facilities and in this process we are building 2 additional production blocks at Unit-1 at Choutuppal. Capital WIP as at the year-end amounted to Rs 11976 lakhs. Capital expenditure incurred at the existing Units is to enhance capacities as well as upgrading utilities and infrastructure for compliances. As the company has significant accumulation of cash reserves, all capex has been funded with internal accruals. In order to cater to the increasing opportunities in generic and big pharma business, the Company during the FY2019, is taking up following two brownfield projects with an aggregate investment of Rs 1200 crore.a. An SEZ Unit at our Unit-II at Visakhapatnam, named as DCV SEZ Unit, with an investment of Rs 600 crore. (revised from the estimate of Rs 400 crore announced at the last General Meeting),b. Another SEZ Project with an investment of Rs 600 crore in the available land at our Unit-I in Bhuvangiri-Yadadri (erstwhile Nalgonda) District, Telangana State. The Company has commenced commercial operations from a part of the DC-SEZ Unit in February, 2020, and from a part of the DCV-SEZ Unit in March 2020. The Company has also taken up debottlenecking programs at Unit-I as well as Unit-II by investing an aggregate amount of Rs 300 crore -which would also create additional capacities for existing products. In addition, the company also taken up augmentation of waste treatment infrastructure at Unit-II at an estimated cost of Rs 150 crore. A part of the backward integration, debottlenecking and utility expansion projects have come into utilization this year. The rest of these projects will be completed and come into utilization by end of second half of financial year 2020-21. The balance works of the brownfield projects of DC-SEZ and DCVSEZ are also expected to be completed by second half of financial year 2020-21. As on 31 March 2020, the company has two overseas subsidiaries M/s. Divis Laboratories (USA) Inc., in the United States of America and M/s. Divi's Laboratories Europe AG in Switzerland for marketing its Nutra products. Eventhough there was a nationwide lockdown restrictions due to COVID-19 pandemic since March 24, 2020, the Government has exempted manufacturing units of essential goods including drugs and pharmaceuticals, medical devices, their raw materials and intermediates from the lockdown restrictions, amongst others. The Company has been operating in compliance with the various advisories/ guidelines passed by the Government of India, State Governments and statutory institutions. The new brownfield DC and DCV SEZ Units and the debottlenecking / backward integration programs taken up by the company during the last year, have become fully operational during the FY2021. Also Modernization and upgradation of waste water treatment plants at the manufacturing sites has been implemented. During the year 2020-21, the company also taken up another capex program with an estimated investment of Rs 400 crore for fast-tracking a customs synthesis project. A part of the project has been completed and became operational and the rest of the capex will be completed during early part of the next financial year i.e.2021-22.

SEBI Single Regn. No. : BSE / NSE / MSMI - INZ0001192537  |   CDSL Reg. No :  IN-DP-CDSL-438-2008                                                                                                                           Filing complaint on SEBI SCORES
Copyright © 2016 All rights reserved Comfort Securities Ltd.
Designed, Developed and content powered by CMOTS Infotech(ISO 9001:2015 certified)
Attention Investors ::
"No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investors account.   |    Kyc is one time exercise while dealing in securities markets:- Once KYC is done through a SEBI Registered Intermediary(Broker DP Mutual Fund etc.) you need not undergo the same process again when you approach another Intermediary.” “ Prevent Unauthorized Transaction in your Trading/Demat account. Update your Mobile Numbers/Email IDs with your Stock Broker/Depository Participant. Receive alerts/information of your transaction/all debit and other important transactions in your Trading/Demat account Directly from Exchange/CDSL at the end of the day. Issued in the Interest of Investors. “ Prevent Unauthorized Transactions in your demat account Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from Depository (NSDL/CDSL) on the same day issued in the interest of investors.